Navigation Links
Fungal spores travel farther by surfing their own wind
Date:9/27/2010

Long before geese started flying in chevron formation or cyclists learned the value of drafting, fungi discovered an aerodynamic way to reduce drag on their spores so as to spread them as high and as far as possible.

One fungus, the destructive Sclerotinia sclerotiorum, spews thousands of spores nearly simultaneously to form a plume that reduces drag to nearly zero and even creates a wind that carries many of the spores 20 times farther than a single spore could travel alone, according to a new study by mathematicians and biologists from the University of California, Berkeley, Harvard University and Cornell University.

"In the Tour de France, riders form a peloton that can reduce air drag by 40 percent," said co-lead author Marcus Roper, a postdoctoral researcher in the Department of Mathematics at UC Berkeley and at Lawrence Berkeley National Laboratory. "The ascospores of Sclerotinia do the peloton perfectly, reducing air drag to zero and sculpting a flow of air that carries them even farther."

Presumably, this strategy helps the fungi get their spores off the ground into the foliage of their host plants, or into airstreams that can carry them to host plants, the scientists say.

Co-lead author Agnese Seminara, a postdoctoral researcher and theoretical physicist in Harvard's School of Engineering and Applied Sciences, added: "I realized that the spores behaved much like cloud droplets. To follow their paths, I adapted algorithms I had developed to describe cloud formation."

Roper, Seminara, and colleagues report the findings this week in the early online edition of the journal Proceedings of the National Academy of Sciences (PNAS).

"These findings could have implications for methods of controlling the spread of fungal pathogens," said senior author Anne Pringle, associate professor of organismic and evolutionary biology at Harvard. "Sclerotinia alone costs U.S. farmers on the order of
'/>"/>

Contact: Robert Sanders
rsanders@berkeley.edu
510-643-6998
University of California -- Berkeley
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Scientists discover how deadly fungal microbes enter host cells
2. 2 new frog species discovered in Panamas fungal war zone
3. Emergence of fungal plant diseases linked to ecological speciation
4. Unexpectedly high rate of multiple strains in fungal infection
5. Emergence of fungal plant diseases linked to ecological speciation
6. Fighting fungal infections with bacteria
7. Diverse wheat tapped for antifungal genes
8. Fungal fumes clear out crop pests
9. New compounds may control deadly fungal infections
10. In the war between the sexes, the one with the closest fungal relationship wins
11. Mounting a multi-layered attack on fungal infections
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fungal spores travel farther by surfing their own wind
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... able to change their spots, but corals can change their ... chemical composition of the seawater around them. , That's the ... writing in the July issue of the journal Geology. ... is the first known case of an animal altering the ...
... born infected with human cytomegalovirus, or CMV, and about ... the virus ?almost one an hour. These disabilities can ... of coordination, and seizures. According to the Centers for ... cause of serious disability as Down syndrome, fetal alcohol ...
... Biologists from Washington University in St. Louis and their ... trees of rice varieties and have determined that the ... Asian locales. , Jason Londo, Washington University in Arts ... A. Schaal, Ph.D., Washington University Spencer T. Olin Professor ...
Cached Biology News:Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Innovative method for creating a human cytomegalovirus vaccine outlined 2Biologists find regions of rice domestication 2
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... , MALVERN, Pa. ... (AMR) and Decision Resources find that the leading driver ... broad-spectrum activity against gram-positive and gram-negative pathogens. Due to ... surveyed European physicians reveal that they look primarily for ...
... ... Top LASIK surgeons and recognized refractive and cataract surgery ... up-to-date on the latest developments in vision correction surgery, cataract surgery, ... Ophthalmology (AAO) annual meeting in San Francisco, California. Dr. Richard Lindstrom, ...
... VIENNA, Austria, November 19 AFFiRiS AG ... an unexpectedly early,stage of development: the vaccine candidate AD02 is ... This decision by the company,immediately follows the completion of two ... based its fast decision on the first interim,analysis of the ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3